Carcinoma, Endometrioid - 25 Studies Found Status Study Active, not recruiting Study Name: Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Carcinosarcoma Fallopian Tube Clear Cell Adenocarcinoma Biological: Bevacizumab Given Recruiting Study Name: Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Condition: Clear Cell Adenocarcinoma Fallopian Tube Clear Cell Adenocarcinoma Biological: Bevacizumab Given Recruiting Study Name: Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation Drug: Cediranib Maleate Given Recruiting Study Name: Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Condition: Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation Drug: Cediranib Maleate Given Recruiting Study Name: Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Condition: Endometrial Adenocarcinoma Endometrial Adenosquamous Carcinoma Radiation: 3-Dimensional Conformal Radiation Therapy <<< Previous